Replimune

$29.61 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Replimune

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1, RP2, and RP3. The Company is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

Stock Analysis

last close $30.15
1-mo return -3.6%
3-mo return -6.3%
avg daily vol. 206.57T
52-week high 54.85
52-week low 27.66
market cap. $1.4B
forward pe -
annual div. -
roe -24%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 93.6%
baraka

Subscribe now for daily local and international financial news

Subscribe